We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRVL:NASDAQCorVel Corp. Analysis

Data as of 2026-03-27 - not real-time

$53.41

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

CorVel (CRVL) is trading at $53.41, just above its 20‑day SMA of 53.14 but well below the 50‑day (55.87) and 200‑day (75.75) averages, signalling a bearish price momentum. The RSI sits near the neutral zone at 49, while the MACD histogram is positive (0.30) and the signal line is deemed bullish, suggesting a short‑term technical bounce may be possible. The stock is perched between a clear support level of 50.51 and resistance near 55.59, with volume trending upward, which could provide the liquidity needed for a modest rebound.
Fundamentally, CRVL delivers solid profitability—gross margin of 24%, operating margin 13.7%, and a strong ROE of 31%—backed by a robust cash position ($230 M) and minimal debt ($26 M). However, the valuation appears stretched: a trailing P/E of 26 far exceeds the industry average of 16, the price‑to‑book ratio is high at 7.27, and the DCF‑derived fair value of $33.9 suggests a significant discount to the current market price. The stock also exhibits high 30‑day volatility (~28.6%) and a historical max drawdown of over 60%, underscoring notable price risk despite a low beta (0.49) and a stable U.S.‑centric operating footprint.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above 20‑day SMA with bullish MACD histogram
  • Support level at $50.51 offering downside protection
  • Increasing volume indicating short‑term buying interest

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Price remains below 50‑day and 200‑day SMAs, confirming bearish trend
  • Valuation metrics (P/E 26 vs industry 16, DCF fair value $33.9) signal overvaluation
  • High volatility and historical drawdown elevate price risk

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong cash flow generation and high ROE (31%) support sustainable earnings
  • Low debt and ample cash cushion reduce financial risk
  • Secular demand for claims‑management and AI‑driven health‑cost solutions provide growth runway

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin11.23%
P/E Ratio26.2
ROE31.26%
ROA14.44%
Debt/Equity6.91
P/B Ratio7.3
Op. Cash Flow$149.1M
Free Cash Flow$98.3M
Industry P/E16.4

Technical Analysis

TrendBearish
RSI49.1
Support$50.51
Resistance$55.59
MA 20$53.14
MA 50$55.87
MA 200$75.75
MACDBullish
VolumeIncreasing
Fear & Greed Index72.43

Valuation

Fair Value$33.90
GradeOvervalued
TypeBlend

Risk Assessment

Beta0.49
Volatility28.66%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.